BHB Science

βHB is Beta-Hydroxybutyrate, one of three molecules classically defined by physiologists as ketone bodies. Ketone bodies, such as β-hydroxybutyrate (βHB or β-OHB), acetone and acetoacetate (AcAc), are produced in the liver and serve as alternative energy sources for the brain, heart, and skeletal muscle cells. They are produced during glucose deprivation (i.e. starvation), fasting or when consuming low-carbohydrate diets (Yudkoff et al., 2007; Branco et al., 2016). During prolonged fasting, glycogen stores (a source of glucose) are used as the primary energy source. When those stores are exhausted, the level of total blood ketone bodies can increase up to 5-8 mM (Owen et al., 1969). At ketone levels of 0.5 mM or above, it is clinically defined as a state of nutritional ketosis, which spares muscle loss (Veech, 2004; Paoli et al., 2015b), and may boost mitochondrial and neuronal metabolism for a myriad of physical and cognitive benefits (Achanta et al., 2017). In other words, βHB is a water-soluble fat-derived energy metabolite produced in the liver.

 

βHB crosses the blood brain barrier, accumulates in brain tissue and provides a source of energy for the central nervous system (CNS) (Plecko et al., 2002; Yudkoff et al., 2007; Newman and Verdin, 2014; Achanta and Rae, 2017). Preserving brain energy metabolism serves a very important evolutionary function with particular regard to the enormous energy demand of the human brain. Ketones help sustain that demand during glucose energy restriction, as well (Veech et al., 2001; Veech, 2004; Cahill, 2006). Cells of the CNS are not able to use Long Chain Fatty Acids/ Triglycerides (LCTs) as an energy source under normal physiological circumstances: these cells utilize glucose as fuel, and under certain conditions (hypoxia), lactate. During dietary glucose energy restriction from carbohydrate and protein restriction (ketogenic diet; KD), or prolonged fasting, the human metabolism shifts from burning glucose to burning fatty acids and ketones. In the brain exclusively, ketones can become the predominate fuel for the massive energy requirements of the CNS (Cahill, 2006).

 

The ketone bodies—βHB and AcAc—are synthetized by liver cells’ mitochondria from fatty acids, which lead to ketosis when blood ketone levels rise above 0.5 mmol/L (Figure 1.; fatty acid metabolism in liver). These ketone bodies then reach the brain via blood vessels by transporter molecules. Similar to heart and skeletal muscle cells, ketone bodies can metabolize directly to acetyl CoA and provide energy for brain cells, as well as through the Krebs (ATP) cycle (Yudkoff et al., 2007; Newman and Verdin, 2014; Branco et al., 2016; Egan and D’Agostino, 2016; Achanta and Rae, 2017). While ketone metabolism may appear new, it is interesting to note that βHB is an ancient molecule - from an evolutionary perspective – designed to provide energy when glucose was restricted. For example, many bacteria are able to synthetize βHB polymers to store energy (Cahill, 2006). Moreover, blood levels of βHB, and how βHB is metabolized and used, are all dependent on age, brain area and species. This suggests a different and diversified physiological role of βHB in the body of several species (Hawkins and Biebuyck, 1979; Achanta and Rae, 2017).

 

WHAT ARE THE BENEFITS OF BHB? 

• Alternative and preferred energy source: Despite the fact that the human brain (weighing approximately 1.5 kg) represents 2-3% of body weight, it consumes 20% of the body’s total energy output. βHB represents an alternative form of energy that most of body’s cells, including the brain, can use in many ways (Yudkoff et al., 2007; Pinckaers et al., 2017) (Figure 2.). In fact, the brain is shown to burn ketones preferentially over glucose in two ways: (1) In the developing brain, ketones preserve glucose for the pentose phosphate pathway, which results in ribose for DNA synthesis and NADPH for lipid biosynthesis and (2) under conditions of long-term starvation and KD, metabolism shifts from burning glucose to fatty acids and ketones as fuel. Under different conditions from above, glucose is the predominate fuel for the brain (Nehlig, 2004; Cahill, 2006). The brain is like a hybrid engine, able to switch from ketones to glucose and vice versa. Interestingly, it can even burn a third fuel—lactate—for energy (Nehlig and Pereira de Vasconcelos, 1993). For example, one study showed that in 15 day-old rats, glucose was the major fuel (57%); but both βHB (20%) and lactate (23%) also supported the brain’s energy supply (Dombrowski et al., 1989). These observations show that the brain has a remarkable ability for adaptation and metabolic flexibility.

 

Fourth macronutrient: βHB enhances mitochondrial energy production (as a “high-octane” fuel), or as a molecule that can provide unique health benefits that are completely independent of its role as an energy metabolite (Hashim and VanItallie, 2014; Newman and Verdin, 2014; Cox et al., 2016; Dyer, 2016; Egan and D’Agostino, 2016).

 

• Suppression of oxidative stress and inflammatory processes: Partly by suppression of oxidative stress and inflammatory processes, ketosis/βHB may improve the symptoms of different diseases such as Parkinson’s disease, Alzheimer’s disease, schizophrenia, amyotrophic lateral sclerosis (ALS), glucose transporter 1 (GLUT1)-deficiency syndrome, anxiety, autism, depression, cancer, and epilepsy not only in model animals of different human diseases but also in patients (Masino et al., 2009; Stafstrom and Rho, 2012; D’Agostino et al., 2013; Shimazu et al., 2013; Hashim and VanItallie, 2014; Poff et al., 2015; Youm et al., 2015; Ari et al., 2016; Branco et al., 2016; Chavan et al., 2016; Rogawski et al., 2016; Achanta and Rae, 2017; Bostock et al., 2017; Cheng et al., 2017; Rho, 2017; Simeone et al., 2017; Tefera et al., 2017).

 

• Improvement of cognitive functions: βHB improved cognitive functioning (e.g., working memory and executive function) in both memory-impaired patients and in healthy non-demented subjects (Reger et al., 2004; Krikorian et al., 2012; Ota et al., 2016).

 

• Reduction in seizure activity: Approximately 50% reduction in seizure activity was demonstrated in 50-60% of children with drug-resistant childhood epilepsy after KD, which effect may be in relation, among others, to progressive elevation of serum ketone bodies/βHB (Ross et al., 1985; Groomes et al., 2011; Thammongkol et al., 2012; Kim et al., 2016). 

 

Homeostatic role: βHB is one of the main components of homeostatic mechanisms, which allow us to survive prolonged starvation. For example, βHB negatively regulates its own synthesis preventing life-threatening high-level ketoacidosis (ketoacidosis is explained later in this white paper) and promotes effective use of fat tissue (as an energy store) under this circumstance (Taggart et al., 2005).

 

• Longevity-enhancing effects: βHB could also have longevityenhancing effects (Newman and Verdin, 2014; Veech et al 2017). In C. elegans (roundworms), βHB was shown to increase lifespan through inhibiting histone deacytelase (HDAC) and reducing metabolic stress (Edwards et al, 2014). 

 

Reduction of hunger (cravings) and effect on weight management: Nutritional ketosis/βHB plays a role in regulating food intake and body weight (Atkins, 2002; Paoli, 2014; Paoli et al., 2015a). Different hypotheses suggest the indirect and direct mechanisms by which KD/nutritional ketosis/ketone bodies induce and evoke weight loss: (i) Losing energy by excretion of ketone bodies, (ii) gluconeogenesis (which converts protein to glucose and provides a major portion of the glucose needed for fuel during the initial period of KD) is an energy-demanding process leading to a “waste of calories”, (iii) higher satiety effect of proteins, which evoke reductions in appetite, (iv) increased lipolysis and decreased lipogenesis and (v) a possible direct suppressive effect of ketone bodies (e.g., βHB) on appetite/ hunger (Kekwick and Pawan, 1957; Atkins, 2002; Cahill, 2006; Feinman and Fine, 2007; Johnstone et al., 2008; WesterterpPlantenga et al., 2009; Sumithran et al., 2013). In the Kekwick and Pawan study in 1957, the researchers showed that you can consume the same number of calories in fat, protein and carbs, but you expend the most energy (calories) when consuming fat. In other words, a calorie is not a calorie. Also, the ketogenic diet/nutritional ketosis is characterized by increased circulating free fatty acid levels, which may reduce food intake and glucose production through specific neurons from parts of the brain implicated in regulation of satiety and hunger (Paoli et al., 2015a). Thus, among others, beneficial effects of increased levels of both free fatty acids and βHB on body weight suggests that KD/ketosis may be a good way to manage weight.

 

• Insulin sensitivity: βHB enhances insulin sensitivity (Will et al., 1997; Veech, 2004; Park et al., 2011). 

 

Improvement of reaction time and exercise performance: βHB may improve them both due to its use as an alternative substrate for ATP (Cox et al., 2016; Egan and D’Agostino, 2016). Additionally, βHB spares glycogen and Leucine (Nair et al, 1988).

 

• Intermittent fasting: Consumption of βHB may preserve and maintain brain energy metabolism during periods of limited glucose availability.

 

.• Alleviation of the keto “flu” symptoms: Keto “flu” (or ketogenic/ ketosis flu, low-carb flu, induction flu, Atkins flu) is a withdraw symptom from carbohydrate restriction, which occurs when the body is adapting to burning ketones rather than glucose. Thus, to decrease the symptoms of keto “flu” (e.g., fatigue, headache, nausea, dizziness, sleepiness, and difficulty focusing or brain fog), consumption of more fat, or βHB, may be recommended (Stanton, 2011).

 

 

WHAT ARE THE TOP REASONS FOR TAKING EXOGENOUS KETONES? 

The main benefits to using βHB will be somewhat dependent upon the end-user. We know that βHB has the unique property of enhancing bioenergetic effects (much like creatine, but more versatile), thus consuming βHB as a supplement has the potential to enhance our overall metabolic health and even performance. (Abraham, 2015; Cox et al., 2016; Egan and D’Agostino, 2016; Pinckaers et al., 2017). For example, the use of βHB may be especially beneficial for populations of people that have insulin resistance or carbohydrate intolerance. Evidence suggests that βHB can enhance insulin sensitivity and may improve glucose disposal (Will et al., 1997; Veech, 2004; Park et al., 2011). A large percentage of the population above middle age has either signs of insulin resistance or is considered pre-diabetic. 

 

It seems that the most promising application of exogenous ketones as a supplement is that it can be used as a source of energy to further augment one’s own diet or perhaps a low-carbohydrate KD (less than 50 g/day carbohydrates) (Veech, 2004; Paoli et al., 2013). When it comes to using βHB as a supplement together with the KD, this may present a number of compelling benefits. For example, when one starts a KD, one’s brain essentially goes through a form of “glucose withdrawal” that can negatively impact physical and cognitive performance. This usually occurs over several days, or as long as two to four weeks, and causes lethargy, headaches and an overall decrease in mental well-being. But after several weeks the body adapts entirely to using fat and ketones (keto-adaptation) more efficiently for energy. Anecdotally, many users report that βHB makes this transition to a keto or lowcarbohydrate diet more seamless by circumventing the need for extreme dietary restriction to elevate βHB levels. This happens by providing an alternative form of energy that can help to restore and preserve normal brain energy metabolism in the face of carbohydrate restriction as described above. If following a KD, the use of βHB helps to bridge the gap into ketosis by supplying ketones to the brain and also supplying a non-gluconeogenic energy precursor that has less insulin potentiating effect than glucose or protein. Oral intake of βHB will not prevent endogenous ketone production from nutritional ketosis. 

 

Another promising application of exogenous ketones is their consumption during a period of time-restricted eating called intermittent fasting (IF). IF has been shown to have a broad range of health benefits, cognitively, physically and especially for metabolic health in resetting insulin resistance. IF may have therapeutic effect alone or as an adjunct to increase the efficacy of the treatment of different diseases such as cancer, anxiety, neurological diseases and cognitive impairment (Park et al., 2011; Arnason et al., 2017; Hu et al., 2017; O’Flanagan et al., 2017; Singh et al., 2017). Anecdotally, the consumption of small amounts of ketone supplements during a period of intermittent fasting, for example between 10 PM and 4 PM of the next day can provide a person with greater sustained energy without impairing endogenous ketogenesis. Many of the aforementioned benefits are largely a function of preserving and maintaining brain energy metabolism during periods of limited glucose availability and mild hypoglycemia.

 

One of the main benefits of elevated βHB is that hunger cravings are controlled (satiety) as long as brain energy metabolism is not interrupted by fluctuations in glucose and insulin. Nutritional ketosis plays a vital role in stabilizing and regulating food intake control (Atkins, 2002; Paoli et al., 2015a). Regarding insulin, it has been shown that ingesting sodium-βHB did not change insulin secretion and was well tolerated without adverse effects in human studies (Plecko et al., 2002; Van Hove et al., 2003). More advanced formulas using βHB mineral salts (i.e. in combination with MCTs) and new/more effective methods of their application are being developed to enhance and sustain ketone absorption and utilization and to evolve therapeutic procedures. For example, it has been demonstrated that not only intragastric gavage of βHB salt, but also administration of its 4.2% solution (in drinking water) increased ketonemia/βHB level in rats, which may decrease fat mass and suggests that ketone supplements can increase the effectiveness of the treatment of obesity (Pawan and Semple, 1983; Caminhotto et al., 2017).

 

When it comes to performance, especially during periods of extreme exertion or extreme environment (e.g., military troops, emergency personnel, etc.), the use of βHB supplementation evoked mild ketosis. This may be leveraged to provide resilience in the face of limited glucose or oxygen levels without elevation of free fatty acids (Veech, 2004). The application of βHB as an exogenous fuel may be perceived as beneficial to exercise enthusiasts, high-performance athletes (e.g., elite athletes, and cyclists) and even to corporate executives functioning under high levels of stress due to limited sleep, limited food consumption and nonstop travel associated with their business activities. Indeed, it has been demonstrated that βHB may have distinct benefits for athletes looking to improve their reaction time and performance (Abraham, 2015; Paoli et al., 2015b; Cox et al., 2016; Egan and D’Agostino, 2016). Moreover, exogenous ketone supplements/ βHB as a food supplement may increase endurance performance of warfighters similar to high-performance athletes, providing an alternative substrate for oxidative phosphorylation (ATP), greater muscle fat oxidation and a sparing of muscle glycogen (Cox et al., 2016; Egan and D’Agostino, 2016). Elevating blood ketones may also enhance cardiac function (Puchalska and Crawford, 2017). For example, ketone bodies increased both the hydraulic efficiency of the heart by 28% and synthesis of adenosine triphosphate (ATP) (Kashiwaya et al., 1994).

 

However, probably the most promising application of βHB appears to be as a neurocognitive enhancement strategy and perhaps even a nootropic agent for improving cognitive function and maybe reaction time, which has a broad range of implications for agerelated cognitive decline (Newport et al., 2015; Ota et al., 2016; Mamelak, 2017). It has been demonstrated that βHB preserves the rat hippocampus (Izumi et al., 1998), a brain structure, which has a role for example in memory and cognition (it is interesting to note that hippocampus is one of the first structure of the brain, which suffer damage in dementia generating among others short-term memory loss). In human studies, βHB infusion and ketogenic mealsevoked increase in βHB levels improved cognitive functioning (e.g., working memory and executive function) not only in memoryimpaired patients but also in healthy non-demented subjects (Reger et al., 2004; Krikorian et al., 2012; Ota et al., 2016). βHB increased the cerebral blood flow in healthy people (Hasselbalch et al., 1996), which may evoke ameliorating effect on cognitive functions. Moreover, ketone bodies may protect from cognitive impairment and moodiness evoked by obesity and weight gain (Yancy et al., 2009; Davidson et al., 2013).

 

WHY IS BHB TYPICALLY ATTACHED TO MINERALS? 

βHB is attached to minerals through an ionic bond because βHB is not stable on its own in powder form. The βHB “salt” (calcium, sodium, magnesium or potassium) makes the molecule more palatable, and it’s also a convenient way to deliver critical electrolytes that may otherwise be depleted under conditions of low-carbohydrate dieting. Specifically, the consumption of βHB in a mineral salt form buffers the ketone molecule to reduce the mild acidity that’s associated with the free acid form while supplying free-form electrolytes to help promote a low-carb diet.

 

It is important to consume βHB with balanced minerals in order to help absorption and maintain increased βHB levels as described in animal studies (Paoli et al., 2015b; Kesl et al., 2016; Caminhotto et al., 2017) (Figure 3.). Combining βHB with mineral salts also allows βHB consumption in effective concentrations without leading to gastrointestinal (GI) distress It is interesting to note that ketone salts may be effective in different intravenous and dialysis fluid therapies such as application of sodium- βHB in resuscitation fluids in combat casualties (Veech, 2004). There is currently a patent application that covers the mixture of all four of the BHB salts used together (calcium, magnesium, potassium, sodium).

 

 

WHAT IS THE BEST WAY TO BALANCE THE MINERALS? 

 

One way to balance βHB mineral salts is to have sodium as the predominant mineral, since that can facilitate absorption of many molecules in the gut through co-transporter activation. Potassium, magnesium and calcium would represent at least 50% of the mineral content of the ketone salt in a balanced ratio. This is one general guideline for formulation of a ketone salt that is palatable and tolerable (Plecko et al., 2002; Van Hove et al., 2003; Azzam and Azar, 2013; Kesl et al., 2016). However, due to Potassium βHB’s hygroscopicity (absorbs water and causes clumping in powder formulas), most βHB formulas don’t contain Potassium βHB. Instead, it’s possible to add potassium chloride, for example, to balance the minerals. Or, you could use sodium, calcium and magnesium in a powder, and have a separate liquid Ready-To-Drink (RTD) product using Potassium βHB to stack. RTDs also allow for all four βHB salts to be used without stability issues.

 

βHB salts contain βHB and sodium (Na+), potassium (K+), calcium (Ca2+) and/or magnesium (Mg2+) ions. As ketone bodies have diuretic effects and cause a loss of certain amounts of salts, βHB “salt” content helps compensate for the loss without serious side effects if keeping to normal dosing (Veech, 2004). It should be noted that the sodium in sodium βHB is not sodium chloride (aka, table salt), the type of sodium people normally attribute to a rise in blood pressure.

 

APPROPRIATE DOSING FOR VARIOUS OUTCOMES (WEIGHT MGMT. (SATIETY), COGNITION, PERFORMANCE,…)

 

The best dosing strategy for βHB salts is to start at a relatively low dose - about 6 g per serving. Gradually increase the dose every three days in order to achieve the desired energy performance and GI tolerability. However, to achieve therapeutic level of ketone bodies (1-5 mM) in the blood of a 70 kg man, it can range from 5.6 g to 63 g/day of βHB salts (Veech, 2004), depending on the goal of the user and/or type of disease state. In dietary supplements, the typical therapeutic dose is in the 12 g range, and some combine it with 3-7 g of MCT for higher and more sustained levels of blood ketones. After ingesting a βHB supplement, increased levels of blood ketones may decrease to the normal physiological levels within several hours (Figure 3.). Thus, to achieve and maintain desired therapeutic levels of βHB, it’s wise to time your ketogenic/ βHB supplement to achieve your goal (e.g., before a meal, during intermittent fasting, prior to exercise, before difficult cognitive tasks, for long-lasting energy and other goals unique to you). 

 

WHAT IS THE COMPLEMENTARY ACTION BETWEEN ΒHB AND MCT; AND WHAT OTHER INGREDIENTS GO WELL WITH ΒHB?

 

The combination of βHB with medium chain triglycerides (MCTs) enhances the overall elevation of βHB in the blood by facilitating endogenous ketone production (from MCTs) in addition to the exogenous βHB source. It delays gastric absorption to extend and sustain the elevation of blood ketone levels over a longer period of time (Kesl et al., 2016). Therefore, it is easier to achieve a higher level of blood βHB then if they used either βHB salt orMCT alone. Emerging data on a number of animal models and anecdotal reports in humans have validated the combination of βHB with MCT as being superior (Azzam and Azar, 2013; Kesl et al., 2016). It was also described that the combination of MCT oil with βHB mineral salt effectively increased the level of βHB and abolished the adverse GI effects of MCT oil alone such as diarrhea and flatulence (Azzam and Azar, 2013; Kesl et al., 2016). However, more studies are needed to determine what dosage and ratio is optimal. Other ingredients that go well with βHB include branched-chain amino acids for buffering and an anti-catabolic affect, as well as various digestion-resistant prebiotic soluble fibers to ensure a healthy and robust gut microbiome (Stilling et al., 2016). 

 

ARE THERE PATENTS ASSOCIATED WITH BHB?

Yes, there are patents concerning BHB, the combination of BHB and MCT, and patent-pending on the combination of all four BHB salts. Compound Solutions is the official distributor of patented BHB and MCT under the trademarks goBHB™ and goMCT™

 

WHAT IS THE DIFFERENCE BETWEEN D AND DL AND WHICH IS THE BETTER VALUE? 

More research is needed to determine whether D-βHB or DLβHB is superior. DL is known as racemic (DL indicates an equal (1:1) mixture of dextro and levo isomers). There is some evidence to suggest that the D form may be superior for enhancing mitochondrial function whereas some evidence suggests the DL form is superior for specific types of neurological diseases and cancer (Van Hove et al., 2003; Veech, 2004; Taggart et al., 2005; Gautschi et al., 2015). The body converts some portion of L-BHB to D-BHB; and L-BHB is thought to be a signaling molecule to reduce the inflammation associated with the diseases above. But experiments are ongoing to determine if one form is more beneficial than the other. To the best of our knowledge at this time, there is no comprehensive study to determine if D-βHB is more beneficial than DL regarding general use applications, or value to the consumer from a financial perspective. In regards to elevating blood ketone levels, D-βHB will appear to generate a higher level of blood βHB because the commercially available measurement devices only measure the D form of βHB, not the L form. If ketone blood measurements are done using gas chromatography or mass spectrography, the total level of βHB including D and L will be measured correctly and the rise in βHB from consuming D or consuming DL should be identical.

 

WHAT ARE POTENTIAL DOWNSIDES? 

The primary potential downside of ketone supplementation is GI discomfort which is associated with the mineral load that can cause an osmotic diarrhea (Plecko et al., 2002; Van Hove et al., 2003; Azzam and Azar, 2013; Kesl et al., 2016). It typically occurs with higher levels of βHB and MCT combined. This side effect of βHB supplementation can be significantly reduced by consuming adequate amounts of water, limiting the dosage and gradually increase the dosage over time to improve tolerability. Consuming ketone salts with a meal can also improve tolerability.

 

AT WHAT DOSE OF BHB DO SOME TYPICALLY FIND GI DISTRESS? 

As the effectiveness of ketone bodies and their tolerability may vary in each person, GI distress can occur at dosages as little as  5 g/day in the most sensitive populations. But dosages as high as 50 g/day are well tolerated in many people using βHB supplements. In terms of recommended βHB dosage, it is 11 – 13 g/serving (Denton, 2016). 

 

AT WHAT DOSE OF ΒHB AND MCT DO PEOPLE START TO FEEL GI DISTRESS?

“Gradualism” is the key. At levels of about 5g each of βHB and MCT, some very sensitive people start to feel GI distress. Individual sensitivity requires starting at lower doses and gradually adding ketones until striking a balance between effectiveness and GI tolerability.

 

DOES TAKING EXOGENOUS KETONES ACTUALLY PUT SOMEONE INTO KETOSIS?

Yes, taking exogenous ketone supplements will elevate normal blood plasma βHB levels into a range that is clinically accepted as being in a state of ketosis (>0.5 mM) (Achanta and Rae, 2017). 

It must be recognized that nutritional/physiological ketosis is much different from pathological ketosis (“ketoacidosis”) that is a consequence of type I diabetes (and type 2 diabetes to a lesser extent) and other pathological states. For example, in physiological ketosis (e.g. during very-low-calorie KD and use of exogenous ketone supplements), the level of ketones are not able to go higher than 7-8 mM because, cells of the CNS use ketone bodies efficiently for energy production. Thus, under nutritional ketosis or supplemental ketones, blood pH does not change. Ketoacidosis cannot occur. In the case of diabetic ketoacidosis, ketone body levels can increase up to 20-25 mM, which decreases blood pH (Paoli et al., 2013, 2015b).

 

CAN I BENEFIT FROM EXOGENOUS KETONES IF I’M NOT EATING KETOGENICALLY?

Yes, someone not eating a KD or carbohydrate-restricted diet can benefit from consumption of βHB salts due to the fact that this will allow an elevation of βHB in the blood, which we know is linked to many health benefits described above; some of which have been documented in humans (Pinckaers et al., 2017). More research is needed to move the preclinical animal studies into human clinical studies to validate the use of βHB supplementation.

 

SHOULD THOSE IN NUTRITIONAL KETOSIS TAKE EXOGENOUS KETONES?

The use of exogenous ketones for performance applications has been exclusively in the realm of special operations forces and elite level endurance athletes that have described significant benefits for specific applications (Egan and D’Agostino, 2016; D’Agostion et. al., 2013; Abraham, 2015; Pinckaers et al., 2017). Similar to creatine supplementation, we will elucidate what types of exercise and what types of sports will benefit most from ketone supplementation as the science progresses (Cox et al., 2016). It will be important for the end-user to experiment with the dosing of ketones according to their own performance regimen since other factors, - including body size, type of exercise, duration, existing nutrition strategy and other supplements - will influence the performance-enhancing benefits of βHB supplementation (Pinckaers et al., 2017). Those already in a state of nutritional ketosis can also benefit from βHB supplementation by allowing the user to optimize blood levels of ketones that they have found correlate with optimal mental and cognitive performance.

 

References

1. Abraham R. Ketones: controversial new energy drink could be next big thing in cycling. 2015. http://www.cyclingweekly.co.uk/news/ latest-news/ketones-controversial-new-energy-drink-next-big-thingcycling-151877. Accessed 14 June 2017.

 

2. Achanta LB, Rae CD. β-Hydroxybutyrate in the brain: One molecule, multiple mechanisms. Neurochem Res. 2017 Jan;42(1):35-49. doi: 10.1007/s11064-016-2099-2.

 

3. Achanta LB, Rowlands BD, Thomas DS, Housley GD, Rae CD. β-Hydroxybutyrate Boosts Mitochondrial and Neuronal Metabolism but is not Preferred Over Glucose Under Activated Conditions. Neurochem Res. 2017 Jun;42(6):1710-1723. doi: 10.1007/s11064-017-2228-6.

 

4. Ari C, Kovács Z, Juhasz G, Murdun C, Goldhagen CR, Koutnik AP, Poff AM, Kesl SL, D’Agostino DP. Exogenous Ketone Supplements Reduce Anxiety-Related Behavior in Sprague-Dawley and Wistar Albino Glaxo/ Rijswijk Rats. Front Mol Neurosci. 2016 Dec 6;9:137. doi: 10.3389/ fnmol.2016.00137. eCollection 2016.

 

5. Arnason TG, Bowen MW, Mansell KD. Effects of intermittent fasting on health markers in those with type 2 diabetes: A pilot study. World J Diabetes. 2017 Apr 15;8(4):154-164. doi: 10.4239/wjd.v8.i4.154.

 

6. Atkins RC. Dr. Atkins’ new diet revolution. New York: Avon, 2002.

 

7. Azzam R, Azar NJ. Marked seizure reduction after MCT supplementation. Case Rep Neurol Med. 2013;2013:809151. doi: 10.1155/2013/809151.

 

8. Bostock EC, Kirkby KC, Taylor BV. The current status of the ketogenic diet in psychiatry. Front Psychiatry. 2017 Mar 20;8:43. doi: 10.3389/ fpsyt.2017.00043. eCollection 2017.

 

9. Branco AF, Ferreira A, Simões RF, Magalhães-Novais S, Zehowski C, Cope E, Silva AM, Pereira D, Sardão VA, Cunha-Oliveira T. Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur J Clin Invest. 2016 Mar;46(3):285-98. doi:

 

10.1111/eci.12591. 10. Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1-22.

 

11. Caminhotto RO, Komino ACM, de Fatima Silva F, Andreotti S, Sertié RAL, Boltes Reis G, Lima FB. Oral β-hydroxybutyrate increases ketonemia, decreases visceral adipocyte volume and improves serum lipid profile in Wistar rats. Nutr Metab (Lond). 2017 Apr 24;14:31. doi: 10.1186/s12986017-0184-4. eCollection 2017.

 

12. Chavan R, Feillet C, Costa SS, Delorme JE, Okabe T, Ripperger JA, Albrecht U. Liver-derived ketone bodies are necessary for food anticipation. Nat Commun. 2016 Feb 3;7:10580. doi: 10.1038/ ncomms10580.

 

13. Cheng N, Rho JM, Masino SA. Metabolic dysfunction underlying autism spectrum disorder and potential treatment approaches. Front Mol Neurosci. 2017 Feb 21;10:34. doi: 10.3389/fnmol.2017.00034. eCollection 2017.

 

14. Cox PJ, Kirk T, Ashmore T, Willerton K, Evans R, Smith A, Murray AJ, Stubbs B, West J, McLure SW, King MT, Dodd MS, Holloway C, Neubauer S, Drawer S, Veech RL, Griffin JL, Clarke K. Nutritional ketosis alters fuel preference and thereby endurance performance in athletes. Cell Metab. 2016 Aug 9;24(2):256-68. doi: 10.1016/j.cmet.2016.07.010.

 

15. D’Agostino DP, Pilla R, Held HE, Landon CS, Puchowicz M, Brunengraber H, Ari C, Arnold P, Dean JB. Therapeutic ketosis with ketone ester delays central nervous system oxygen toxicity seizures in rats. Am J Physiol Regul Integr Comp Physiol. 2013 May 15;304(10):R829-36. doi: 10.1152/ ajpregu.00506.2012. Epub 2013 Apr 3.

 

16. Davidson TL, Hargrave SL, Swithers SE, Sample CH, Fu X, Kinzig KP, Zheng W. Inter-relationships among diet, obesity and hippocampaldependent cognitive function. Neuroscience. 2013 Dec 3;253:110-22. doi: 10.1016/j.neuroscience.2013.08.044.

 

17. Denton, M. Beta Hydroxybutyrate. 2016. https://www.nootropedia.com/ beta-hydroxybutyrate/. Accessed 14 June 2017

 

18. Dombrowski GJ Jr, Swiatek KR, Chao KL. Lactate, 3-hydroxybutyrate, and glucose as substrates for the early postnatal rat brain. Neurochem Res. 1989 Jul;14(7):667-75.

 

19. Dyer E. Ketogenic diet and the “4th” macronutrient, 2016; http://www. esupplements.com/article/keto-diet-and-the-fourth-macro/. Accessed 14 June 2017

 

20. Egan B, D’Agostino DP. Fueling performance: ketones enter the mix. Cell Metab. 2016 Sep 13;24(3):373-5. doi: 10.1016/j.cmet.2016.08.021.

 

21. Feinman RD, Fine EJ. Nonequilibrium thermodynamics and energy efficiency in weight loss diets. Theor Biol Med Model. 2007 Jul 30;4:27.

 

22. Gautschi M, Weisstanner C, Slotboom J, Nava E, Zürcher T, Nuoffer JM. Highly efficient ketone body treatment in multiple acyl-CoA dehydrogenase deficiency-related leukodystrophy. Pediatr Res. 2015 Jan;77(1-1):91-8. doi: 10.1038/pr.2014.154.

 

23. Groomes LB, Pyzik PL, Turner Z, Dorward JL, Goode VH, Kossoff EH. Do patients with absence epilepsy respond to ketogenic diets? J Child Neurol. 2011 Feb;26(2):160-5. doi: 10.1177/0883073810376443.

 

24. Hashim SA, VanItallie TB. Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester. J Lipid Res. 2014 Sep;55(9):181826. doi: 10.1194/jlr.R046599.

 

25. Hasselbalch SG, Madsen PL, Hageman LP, Olsen KS, Justesen N, Holm S, Paulson OB. Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. Am J Physiol. 1996 May;270(5 Pt 1):E74651.

 

26. Hawkins RA, Biebuyck JF. Ketone bodies are selectively used by individual brain regions. Science. 1979 Jul 20;205(4403):325-7.

 

27. Hu Y, Yang Y, Zhang M, Deng M, Zhang JJ. Intermittent fasting pretreatment prevents cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Nutr. 2017 May 17. pii: jn245613. doi: 10.3945/ jn.116.245613. [Epub ahead of print]

 

28. Izumi Y, Ishii K, Katsuki H, Benz AM, Zorumski CF. Beta-Hydroxybutyrate fuels synaptic function during development. Histological and physiological evidence in rat hippocampal slices. J Clin Invest. 1998 Mar 1;101(5):112132.

 

29. Johnstone AM, Horgan GW, Murison SD, Bremner DM, Lobley GE. Effects of a high-protein ketogenic diet on hunger, appetite, and weight loss in obese men feeding ad libitum. Am J Clin Nutr. 2008 Jan;87(1):4455.

 

30. Kashiwaya Y, Sato K, Tsuchiya N, Thomas S, Fell DA, Veech RL, Passonneau JV. Control of glucose utilization in working perfused rat heart. J Biol Chem. 1994 Oct 14;269(41):25502-14.

 

31. Kekwick A, Pawan GL. Metabolic study in human obesity with isocaloric diets high in fat, protein or carbohydrate. Metabolism. 1957 Sep;6(5):44760.

 

32. Kesl SL, Poff AM, Ward NP, Fiorelli TN, Ari C, Van Putten AJ, Sherwood JW, Arnold P, D’Agostino DP. Effects of exogenous ketone supplementation on blood ketone, glucose, triglyceride, and lipoprotein levels in Sprague-Dawley rats. Nutr Metab (Lond). 2016 Feb 4;13:9. doi: 10.1186/s12986-016-0069-y. eCollection 2016.

 

33. Kim JA, Yoon JR, Lee EJ, Lee JS, Kim JT, Kim HD, Kang HC. Efficacy of the classic ketogenic and the modified Atkins diets in refractory childhood epilepsy. Epilepsia. 2016 Jan;57(1):51-8. doi: 10.1111/epi.13256.

 

34. Klee CB, Sokoloff L. Changes in D(-)-beta-hydroxybutyric dehydrogenase activity during brain maturation in the rat. J Biol Chem. 1967 Sep 10;242(17):3880-3.

 

35. Krikorian R, Shidler MD, Dangelo K, Couch SC, Benoit SC, Clegg DJ. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol Aging. 2012 Feb;33(2):425.e19-27. doi: 10.1016/j. neurobiolaging.2010.10.006.

 

36. Mamelak M. Energy and the Alzheimer brain. Neurosci Biobehav Rev. 2017 Apr;75:297-313. doi: 10.1016/j.neubiorev.2017.02.001.

 

37. Masino SA. Ketogenic Diet and Metabolic Therapies: Expanded Roles in Health and Disease. Oxford University Press, 2016.

 

38. Masino SA, Kawamura M, Wasser CD, Pomeroy LT, Ruskin DN. Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity. Curr Neuropharmacol. 2009 Sep;7(3):257-68. doi: 10.2174/157015909789152164.

 

39. Nehlig A. Brain uptake and metabolism of ketone bodies in animal models. Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):265-75.

 

40. Nehlig A, Pereira de Vasconcelos A. Glucose and ketone body utilization by the brain of neonatal rats. Prog Neurobiol. 1993 Feb;40(2):163-221.

 

41. Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014 Jan;25(1):42-52. doi: 10.1016/j.tem.2013.09.002.

 

42. Newport MT, VanItallie TB, Kashiwaya Y, King MT, Veech RL. A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer’s disease. Alzheimers Dement. 2015 Jan;11(1):99-103. doi: 10.1016/j. jalz.2014.01.006.

 

43. O’Flanagan CH, Smith LA, McDonell SB, Hursting SD. When less may be more: calorie restriction and response to cancer therapy. BMC Med. 2017 May 24;15(1):106. doi: 10.1186/s12916-017-0873-x.

 


44. Ota M, Matsuo J, Ishida I, Hattori K, Teraishi T, Tonouchi H, Ashida K, Takahashi T, Kunugi H. Effect of a ketogenic meal on cognitive function in elderly adults: potential for cognitive enhancement. Psychopharmacology (Berl). 2016 Oct;233(21-22):3797-3802.

 

45. Owen OE, Felig P, Morgan AP, Wahren J, Cahill GF Jr. Liver and kidney metabolism during prolonged starvation. J Clin Invest. 1969 Mar;48(3):574-83.

 

46. Paoli A. Ketogenic diet for obesity: friend or foe? Int J Environ Res Public Health. 2014 Feb 19;11(2):2092-107. doi: 10.3390/ijerph110202092.

 

47. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr. 2013 Aug;67(8):789-96. doi: 10.1038/ejcn.2013.116.

 

48. Paoli A, Bosco G, Camporesi EM, Mangar D. Ketosis, ketogenic diet and food intake control: a complex relationship. Front Psychol. 2015a Feb 2;6:27. doi: 10.3389/fpsyg.2015.00027. eCollection 2015.

 

49. Paoli A, Bianco A, Grimaldi KA. The ketogenic diet and sport: A possible marriage? Exerc Sport Sci Rev. 2015b Jul;43(3):153-62. doi: 10.1249/ JES.0000000000000050.

 

50. Park S, Kim DS, Daily JW. Central infusion of ketone bodies modulates body weight and hepatic insulin sensitivity by modifying hypothalamic leptin and insulin signaling pathways in type 2 diabetic rats. Brain Res. 2011 Jul 15;1401:95-103. doi: 10.1016/j.brainres.2011.05.040.

 

51. Pawan GL, Semple SJ. Effect of 3-hydroxybutyrate in obese subjects on very-low-energy diets and during therapeutic starvation. Lancet. 1983 Jan 1;1(8314-5):15-7.

 

52. Pinckaers PJ, Churchward-Venne TA, Bailey D, van Loon LJ. Ketone Bodies and Exercise Performance: The Next Magic Bullet or Merely Hype? Sports Med. 2017 Mar;47(3):383-391. doi: 10.1007/s40279-0160577-y.

 

53. Plecko B, Stoeckler-Ipsiroglu S, Schober E, Harrer G, Mlynarik V, Gruber S, Moser E, Moeslinger D, Silgoner H, Ipsiroglu O. Oral β-hydroxybutyrate supplementation in two patients with hyperinsulinemic hypoglycemia: Monitoring of β-hydroxybutyrate levels in blood and cerebrospinal fluid, and in the brain by in vivo magnetic resonance spectroscopy. Pediatric Res. 2002;52:301-6; doi:10.1203/00006450-200208000-00025

 

54. Poff AM, Ward N, Seyfried TN, Arnold P, D’Agostino DP. Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy. PLoS One. 2015 Jun 10;10(6):e0127407. doi: 10.1371/ journal.pone.0127407. eCollection 2015.

 

55. Puchalska P, Crawford PA. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017 Feb 7;25(2):262-284. doi: 10.1016/j.cmet.2016.12.022. Review. PubMed PMID: 28178565

 

56. Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. 2004 Mar;25(3):311-4.

 

57. Rho JM. How does the ketogenic diet induce anti-seizure effects? Neurosci Lett. 2017 Jan 10;637:4-10. doi: 10.1016/j.neulet.2015.07.034.

 

58. Rogawski MA, Löscher W, Rho JM. Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet. Cold Spring Harb Perspect Med. 2016 May 2;6(5). pii: a022780. doi: 10.1101/cshperspect.a022780.

 

59. Ross DL, Swaiman KF, Torres F, Hansen J. Early biochemical and EEG correlates of the ketogenic diet in children with atypical absence epilepsy. Pediatr Neurol. 1985 Mar-Apr;1(2):104-8.

 

60. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R, Ulrich S, Akassoglou K, Verdin E. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013 Jan 11;339(6116):211-4. doi: 10.1126/ science.1227166.

 

61. Simeone TA, Simeone KA, Rho JM. Ketone bodies as anti-seizure agents. Neurochem Res. 2017 Apr 10. doi: 10.1007/s11064-017-2253-5. [Epub ahead of print]

 

62. Singh H, Kaur T, Manchanda S, Kaur G. Intermittent fasting combined with supplementation with Ayurvedic herbs reduces anxiety in middle aged female rats by anti-inflammatory pathways. Biogerontology. 2017 May 6. doi: 10.1007/s10522-017-9706-8. [Epub ahead of print]

 

63. Stafstrom CE, Rho JM. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol. 2012 Apr 9;3:59. doi: 10.3389/fphar.2012.00059. eCollection 2012.

 

64. Stanton J. The science behind the “low carb flu”, and how to regain your metabolic flexibility. 2011, April 26; http://www.gnolls.org/1984/thescience-behind-the-low-carb-flu-and-how-to-regain-your-metabolicflexibility/

 

65. Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF. The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? Neurochem Int. 2016 Oct;99:110-32. doi: 10.1016/j.neuint.2016.06.011.

 

66. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Ketosis and appetite-mediating nutrients and hormones after weight loss. Eur J Clin Nutr. 2013 Jul;67(7):759-64. doi: 10.1038/ ejcn.2013.90.

 

67. Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, Ren N, Kaplan R, Wu K, Wu TJ, Jin L, Liaw C, Chen R, Richman J, Connolly D, Offermanns S, Wright SD, Waters MG. (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem. 2005 Jul 22;280(29):26649-52.

 

68. Tefera TW, Tan KN, McDonald TS, Borges K. Alternative fuels in epilepsy and amyotrophic lateral sclerosis. Neurochem Res. 2017 Jun;42(6):16101620. doi: 10.1007/s11064-016-2106-7.


69. Thammongkol S, Vears DF, Bicknell-Royle J, Nation J, Draffin K, Stewart KG, Scheffer IE, Mackay MT. Efficacy of the ketogenic diet: which epilepsies respond? Epilepsia. 2012 Mar;53(3):e55-9. doi: 10.1111/j.15281167.2011.03394.x.

 

70. Van Hove JL, Grünewald S, Jaeken J, Demaerel P, Declercq PE, Bourdoux P, Niezen-Koning K, Deanfeld JE, Leonard JV. D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet. 2003 Apr 26;361(9367):1433-5.

 

71. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):309-19.

 

72. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr. Ketone bodies, potential therapeutic uses. IUBMB Life. 2001 Apr;51(4):241-7.

 

73. Veech RL, Bradshaw PC, Clarke K, Curtis W, Pawlosky R, King MT. Ketone bodies

 

74. mimic the life span extending properties of caloric restriction. IUBMB Life. 2017

 

75. May;69(5):305-314. doi: 10.1002/iub.1627. Epub 2017 Apr 3. Review. PubMed PMID: 28371201.

 

76. Webber A. To ketone or not to ketone: Mineral salts. http://ketogenic. com/nutrition/ketone-not-ketone-mineral-salts/. Accessed 14 June 2017

 

77. Westerterp-Plantenga MS, Nieuwenhuizen A, Tomé D, Soenen S, Westerterp KR. Dietary protein, weight loss, and weight maintenance. Annu Rev Nutr. 2009;29:21-41. doi: 10.1146/annurevnutr-080508-141056.

 

78. Will JC, Strauss KF, Mendlein JM, Ballew C, White LL, Peter DG. Diabetes mellitus among Navajo Indians: findings from the Navajo Health and Nutrition Survey. J Nutr. 1997 Oct;127(10 Suppl):2106S-2113S.

 

79. Yancy WS Jr, Almirall D, Maciejewski ML, Kolotkin RL, McDuffie JR, Westman EC. Effects of two weight-loss diets on health-related quality of life. Qual Life Res. 2009 Apr;18(3):281-9. doi: 10.1007/s11136-0099444-8.

 

80. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D’Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015 Mar;21(3):263-9. doi: 10.1038/ nm.3804.

 

81. Yudkoff M, Daikhin Y, Melø TM, Nissim I, Sonnewald U, Nissim I. The ketogenic diet and brain metabolism of amino acids: relationship to the anticonvulsant effect. Annu Rev Nutr. 2007;27:415-30.